Literature DB >> 7540657

GD2 oligosaccharide: target for cytotoxic T lymphocytes.

X J Zhao1, N K Cheung.   

Abstract

Carbohydrate antigens rarely provide target epitopes for cytotoxic T lymphocytes (CTL). Disialoganglioside GD2 is a glycolipid expressed at high levels in human tumors and a small group of murine lymphomas (EL4, RBL5, RMA, RMA-S, A13, and BALBRVE). Immunization of C57B1/6 mice with irradiated EL4 cells stimulated a specific CTL response and protected these animals from engraftment of EL4 lymphoma. The CTL activity resided in the CD4-CD8+ population, was dependent on T cell receptor alpha/beta, and was not removed by anti-natural killer cell immunoabsorption, but was restricted to GD2 and H-2b bearing targets. CTL activity could be completely inhibited by GD2-oligosaccharide-specific monoclonal antibodies and their F(ab')2 fragments, but not by immunoglobulin G3 myelomas or antibodies against GD3 or GM2. Soluble GD2 did not inhibit specific tumor lysis. RMA-S lymphoma cells (GD2+H-2b-TAP2 deficient) were resistant to GD2-specific CTL. Sialic acid-containing peptides eluted from EL4 lymphoma cells could (a) stabilize H-2 molecules on RMA-S cells and (b) sensitize them for GD2-specific CTL. Control peptides (derived from vesicular stomatitis virus nucleoprotein peptide and GD2-negative lymphomas) could also stabilize H-2 on RMA-S, but were resistant to GD2-specific CTL. These H-2-binding peptides could be purified by anti-GD2 affinity chromatography. We postulate a new class of naturally occurring epitopes for T cells where branched-chain oligosaccharides are linked to peptides with anchoring motifs for the major histocompatibility complex class I pocket. While analogous to the haptens trinitrophenyl and O-beta-linked acetyl-glucosamine, the potential implications of natural carbohydrates as antigenic epitopes for CTL in biology are considerable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540657      PMCID: PMC2192096          DOI: 10.1084/jem.182.1.67

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  31 in total

1.  Purified MHC class I molecules present hapten-conjugated peptides to TNP/H-2Kb-specific T cell hybridomas.

Authors:  A von Bonin; S Martin; S Plaga; S Hebbelmann; H U Weltzien
Journal:  Immunol Lett       Date:  1993-01       Impact factor: 3.685

2.  Structural complexity of antigenic determinants for class I MHC-restricted, hapten-specific T cells. Two qualitatively differing types of H-2Kb-restricted TNP epitopes.

Authors:  S Martin; A von Bonin; C Fessler; U Pflugfelder; H U Weltzien
Journal:  J Immunol       Date:  1993-07-15       Impact factor: 5.422

3.  Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.

Authors:  H Sabzevari; R A Reisfeld
Journal:  Cancer Res       Date:  1993-10-15       Impact factor: 12.701

4.  Immunization against tumor and minor histocompatibility antigens by eluted cellular peptides loaded on antigen processing defective cells.

Authors:  L Franksson; M Petersson; R Kiessling; K Kärre
Journal:  Eur J Immunol       Date:  1993-10       Impact factor: 5.532

5.  Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.

Authors:  L D Cahan; R F Irie; R Singh; A Cassidenti; J C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

6.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides.

Authors:  C G Ioannides; B Fisk; K R Jerome; T Irimura; J T Wharton; O J Finn
Journal:  J Immunol       Date:  1993-10-01       Impact factor: 5.422

7.  The Rauscher-MuLV-induced leukemia, RBL-5, bears two tumor-associated transplantation antigens expressed on distinct molecules.

Authors:  G Galetto; L W Law; M J Rogers
Journal:  Int J Cancer       Date:  1985-12-15       Impact factor: 7.396

8.  Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3.

Authors:  H Bernhard; J Karbach; W Strittmatter; K H Meyer zum Büschenfelde; A Knuth
Journal:  Int J Cancer       Date:  1993-09-30       Impact factor: 7.396

9.  Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.

Authors:  N K Cheung; A Canete; I Y Cheung; J N Ye; C Liu
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

10.  Recognition of carbohydrate by major histocompatibility complex class I-restricted, glycopeptide-specific cytotoxic T lymphocytes.

Authors:  J S Haurum; G Arsequell; A C Lellouch; S Y Wong; R A Dwek; A J McMichael; T Elliott
Journal:  J Exp Med       Date:  1994-08-01       Impact factor: 14.307

View more
  13 in total

1.  Presentation of cytosolic glycosylated peptides by human class I major histocompatibility complex molecules in vivo.

Authors:  J S Haurum; I B Høier; G Arsequell; A Neisig; G Valencia; J Zeuthen; J Neefjes; T Elliott
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

Review 2.  Advances in chimeric antigen receptor immunotherapy for neuroblastoma.

Authors:  Andras Heczey; Chrystal U Louis
Journal:  Discov Med       Date:  2013-12       Impact factor: 2.970

3.  Impact of minimal tumor burden on antibody response to vaccination.

Authors:  Soo-Kie Kim; Xiaohong Wu; Govind Ragupathi; John Gathuru; Fusataka Koide; Nai-Kong Cheung; Katherine Panageas; Philip O Livingston
Journal:  Cancer Immunol Immunother       Date:  2011-01-26       Impact factor: 6.968

4.  Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Authors:  Assefa Wondimu; Tianqian Zhang; Thomas Kieber-Emmons; Phyllis Gimotty; Katrin Sproesser; Rajasekharan Somasundaram; Soldano Ferrone; Chun-Yen Tsao; Dorothee Herlyn
Journal:  Cancer Immunol Immunother       Date:  2008-07       Impact factor: 6.968

Review 5.  Bridging innate and adaptive antitumor immunity targeting glycans.

Authors:  Anastas Pashov; Bejatolah Monzavi-Karbassi; Gajendra P S Raghava; Thomas Kieber-Emmons
Journal:  J Biomed Biotechnol       Date:  2010-06-15

Review 6.  Cellular immunotherapy for pediatric solid tumors.

Authors:  Meenakshi Hegde; Alexander J Moll; Tiara T Byrd; Chrystal U Louis; Nabil Ahmed
Journal:  Cytotherapy       Date:  2014-07-28       Impact factor: 5.414

Review 7.  Mammalian glycosylation in immunity.

Authors:  Jamey D Marth; Prabhjit K Grewal
Journal:  Nat Rev Immunol       Date:  2008-11       Impact factor: 53.106

Review 8.  Discovery of Cell-Surface Vimentin (CSV) as a Sarcoma Target and Development of CSV-Targeted IL12 Immune Therapy.

Authors:  Izhar S Batth; Shulin Li
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

9.  Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.

Authors:  A Krause; H F Guo; J B Latouche; C Tan; N K Cheung; M Sadelain
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

10.  Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas.

Authors:  Yanfei Xu; Sandra J Gendler; Alessandra Franco
Journal:  J Exp Med       Date:  2004-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.